Cinfa, the Spanish generics group, has gained market leadership with a 23.3% share of the domestic sector, according to IMS Health. Sales last year topped 143.0 million euros ($211.4 million) and this is expected to increase to 163.0 million euros during 2008. Spending on R&D is also set to rise, by around 12.0 million euros. Director general Javier del Rio said that to fall below this level would be a mistake. A total of 72 projects the firm describes as innovations are on the horizon and 50 relate to new products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze